Akari Therapeutics (AKTX) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free AKTX Stock Alerts $1.47 -0.23 (-13.53%) (As of 05/2/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEuropean Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Tradingmsn.com - May 2 at 1:30 PMAkari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.comamericanbankingnews.com - May 2 at 5:24 AMAkari gains despite leadership change amid portfolio shakeupmsn.com - May 1 at 3:39 PMAkari Therapeutics Appoints Samir Patel Interim CEO After CEO Rachelle Jacques Steps Downmarkets.businessinsider.com - May 1 at 10:38 AMSamir R. Patel, M.D. Appointed Interim CEO for Akari Therapeuticsglobenewswire.com - May 1 at 8:01 AMAkari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entityglobenewswire.com - May 1 at 8:00 AMAkari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Drop in Short Interestamericanbankingnews.com - April 26 at 4:04 AMAkari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.comamericanbankingnews.com - April 24 at 2:30 AMAkari Therapeutics Plc: Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024finanznachrichten.de - April 15 at 2:35 PMAkari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024globenewswire.com - April 15 at 8:00 AMEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday Tradingmsn.com - April 12 at 1:17 PMDindin lethal in Akari’s disposal of Capital1msn.com - April 12 at 1:32 AMAkari Therapeutics Insider Ups Holding By 69% During Yearfinance.yahoo.com - April 1 at 4:09 PMAkari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlightsglobenewswire.com - April 1 at 6:30 AMPVL: Fifi Sharma, Ced Domingo power Akari romp of Nxledmsn.com - March 17 at 1:17 AMPetri Dish: C4’s deal with Merck KGaA; Boston and California biotechs mergebizjournals.com - March 7 at 7:10 AMSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NSstockhouse.com - March 6 at 5:40 PMAKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to Shareholdersbusinesswire.com - March 5 at 11:51 AMPVL: Grethcel Soltones, Akari still a work in progressmsn.com - February 27 at 10:23 AMPVL: Ced Domingo has a quiet Akari debut as she adjusts to new systemmsn.com - February 25 at 9:45 AMPVL: Cignal turns back Akari to open All-Filipino bidmsn.com - February 24 at 8:36 AMEuropean Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Tradingmsn.com - February 16 at 12:18 PMPVL: Akari’s Max Juangco taking pressure of her pro debut in stridemsn.com - February 9 at 12:22 PMEuropean Equities Traded in the US as American Depositary Receipts Slightly Lower in Wednesday Tradingmsn.com - February 7 at 2:02 PMEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week Highermsn.com - February 2 at 2:00 PMAkari Therapeutics PLC (AKTX)investing.com - January 23 at 11:28 PMPVL: Faith Nisperos, Akari Chargers aim for Final Fourmsn.com - January 22 at 1:00 AMAkari Therapeutics Plc: Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financingfinanznachrichten.de - January 2 at 10:30 AMAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financingfinance.yahoo.com - January 2 at 10:30 AMAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financingfinance.yahoo.com - January 2 at 10:30 AMAkari Therapeutics Plc - ADR (AKTX) Price Target Increased by 45.45% to 81.60msn.com - December 16 at 5:51 PMAkari Therapeutics to Present at Biotech Showcase 2024finance.yahoo.com - December 14 at 8:44 AMAkari Therapeutics (AKTX) Earnings Dates & Reportsinvesting.com - December 2 at 2:12 PMEuropean Equities Traded in the US as American Depositary Receipts Poised to End Week Flat in Friday Tradingmsn.com - December 1 at 1:33 PMAkari Therapeutics, Plc (CLA.F)sg.finance.yahoo.com - November 28 at 11:19 PMEuropean Equities Traded in the US as American Depositary Receipts Climb Higher Fridaymsn.com - November 24 at 12:59 PMAkari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conferencefinance.yahoo.com - November 16 at 9:43 AMTravel, Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesdaymsn.com - November 14 at 3:37 PMAkari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conferencefinance.yahoo.com - November 6 at 10:25 AMPresenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Nowfinance.yahoo.com - October 3 at 7:28 AMAkari Therapeutics Plc: Akari Therapeutics Reports First Half 2023 Financial Results and Highlightsfinanznachrichten.de - September 29 at 9:16 AMAkari Therapeutics Reports First Half 2023 Financial Results and Highlightsfinance.yahoo.com - September 29 at 9:16 AMAkari Therapeutics to Present at Emerging Growth Conferencefinance.yahoo.com - September 27 at 12:36 PMAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Creditfinance.yahoo.com - September 21 at 12:40 PMAkari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needsfinance.yahoo.com - September 19 at 8:13 AMAkari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirementfinance.yahoo.com - September 5 at 8:27 AMAkari Therapeutics Plc - ADR (AKTX) Price Target Increased by 1900.00% to 56.10msn.com - August 31 at 7:09 PMBritish pharma opens U.S. headquarters in Bostonfinance.yahoo.com - August 21 at 5:21 PMAkari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trialsfinance.yahoo.com - August 18 at 8:07 AMmarketbeat.com - August 17 at 10:28 AM Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Dems have chosen Biden replacement? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election. See who it is HERE. AKTX Media Mentions By Week AKTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKTX News Sentiment▼0.180.33▲Average Medical News Sentiment AKTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKTX Articles This Week▼71▲AKTX Articles Average Week Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aeterna Zentaris News Today Alterity Therapeutics News Today Elevai Labs News Today Moleculin Biotech News Today Guardion Health Sciences News Today Galera Therapeutics News Today Eterna Therapeutics News Today NuCana News Today Molecular Templates News Today Virios Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKTX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
